Azad Mojahedi

Azad Mojahedi

Auto-generated profile, based on publicly available information

Azad Mojahedi

Department of Internal Medicine, Stony Brook University Hospital, Stony Brook, NY 11794, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
AMAzad Mojahedi
Azad Mojahedi
Andreas KalogeropoulosAndreas Kalogeropoulos
Andreas Kalogeropoulos
OCOn Chen
On Chen
HSHal Skopicki
Hal Skopicki
Background: Contrast-induced acute kidney injury (CI-AKI) represents a significant cause of acute kidney injury (AKI) and accounts for 11% of all cases. Conventional biomarkers, such as serum creatinine (SCr), present limitations in terms of sensitivity and specificity for the early detection of CI-AKI. Therefore, this review examines the potential of cystatin C (CysC) as a biomarker for predicting CI-AKI in patients undergoing coronary procedures and assesses its effectiveness compared to traditional markers. Methods: This systematic review was conducted using PubMed to identify studies published between January 2020 and March 2025. The inclusion criteria focused on original studies examining CysC levels for early CI-AKI detection in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI). Data extraction followed a standardized charting method, focusing on key findings from the selected studies. Results: A total of 7 studies met the inclusion criteria from an initial pool of 410 articles, with data extracted from these seven prospective studies. Key findings indicated that elevated preoperative CysC levels correlated with a higher risk of developing CI-AKI, demonstrating greater sensitivity and specificity than the conventional SCr biomarker. The mean cut-off values for CysC varied across studies, but consistent trends highlighted its potential as an early indicator of renal dysfunction. Conclusions: CysC appears to be a more sensitive biomarker than SCr for the early detection of CI-AKI. This review suggests that integrating CysC measurement into clinical practice could enhance the early diagnosis and management of CI-AKI, ultimately improving patient outcomes. Hence, future research should focus on standardizing CysC cut-off values and further explore their implications in broader clinical settings and guidelines.

1 January 2024 in American Journal of Cardiovascular Disease
Verified
Journal Article
Closed access
AMAzad Mojahedi
Azad Mojahedi
AMAfsaneh Mirshekari
Afsaneh Mirshekari
Supraventricular tachycardia (SVT) is the most prevalent arrhythmia observed in infants, impacting individuals with or without congenital cardiac dysfunction. Infantile-onset SVT typically manifests within the initial one to two months of life. A variety of anti-arrhythmic medications are employed to treat SVT in infants during their first year of life. Nevertheless, a consensus has yet to be reached on the most efficacious drug, and treatment approaches continue to vary considerably As SVT remains a frequent problem around the world, with different management approaches and no obvious optimal option, we conducted a systematic review of the new update of antiarrhythmic drugs for managing SVT in infants under one year old.

22 September 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
AMAzad Mojahedi
Azad Mojahedi
OCOn Chen
On Chen
HSHal A Skopicki
Hal A Skopicki
TRTahmid Rahman
Tahmid Rahman
ASAmirhossein Sadeghian
Amirhossein Sadeghian
Background: Despite advancements in treatment, coronary artery disease (CAD) remains a significant global health concern. Although lipoprotein(a) [Lp(a)] is recognized as a crucial cardiovascular risk factor associated with increased risk, the prognostic value of using Lp(a) levels in patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI) remains debatable. This review aimed to investigate the association between Lp(a) levels and recurrent ischemic events in patients with ACS undergoing PCI. Methods: This systematic review included studies with individuals aged ≥18 years diagnosed with ACS who underwent PCI and had Lp(a) measurements. The included studies were sourced from the PubMed database, with a focus on articles published between January 2020 and January 2025. Keywords related to Lp(a) and cardiovascular diseases were used in the search. Data extraction involved a review of titles and abstracts followed by quality assessment using the QUADAS-2 tool. Results: The final analysis included 10 studies with a combined population of 20,896 patients from diverse regions, including Japan, India, Egypt, China, and South Korea. Key findings indicate that elevated Lp(a) levels are significantly associated with adverse cardiovascular outcomes, including myocardial infarction and mortality, both in hospital and during long-term follow-up. Conclusions: This review highlights Lp(a) as a critical biomarker for predicting recurrent cardiovascular events in ACS patients post-PCI. The consistent correlation between elevated Lp(a) levels and adverse outcomes underscores the necessity of routine monitoring and targeted management of Lp(a) to mitigate residual cardiovascular risk.

1 January 2025 in American Journal of Cardiovascular Disease
Verified
Journal Article
Closed access
ABAmirbehzad Bagheri
Amirbehzad Bagheri
AMAzad Mojahedi
Azad Mojahedi
BRBrian P Rosario
Brian P Rosario
PRPatrick G Rosario
Patrick G Rosario
GGGennady Geskin
Gennady Geskin
Rotational atherectomy device entrapment is a rare but challenging complication of peripheral vascular interventions. This case report details a novel dual-access endovascular technique for retrieving an entrapped atherectomy burr from the posterior tibial artery of a 70-year-old man with severe peripheral arterial and chronic kidney disease. When conventional retrieval methods failed, retrograde posterior tibial access was established as an adjunct to the existing femoral access, enabling sequential balloon angioplasty with progressively larger balloons (1.5-2.5 mm) around the entrapped device. This dual-access approach successfully liberated the burr without requiring surgical extraction or arteriotomy. Following device retrieval, definitive treatment with balloon angioplasty and stent placement was completed immediately, achieving excellent restoration of flow. This minimally invasive technique offers several advantages over traditional surgical approaches, including vessel patency preservation, reduced procedural morbidity, avoidance of general anesthesia, and protection of potential future bypass targets. The described methodology expands the endovascular options for managing complex device-related complications and demonstrates particular value in high-risk patients with significant comorbidities.

20 May 2025 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
FRFarshad Riahi
Farshad Riahi
STSeyed Hamed Tooyserkani
Seyed Hamed Tooyserkani
ASAmirhossein Sadeghian
Amirhossein Sadeghian
SASara Azizollahi
Sara Azizollahi
ASArmin Sourani
Armin Sourani
AMAzad Mojahedi
Azad Mojahedi

1 January 2025 in International Journal of Burns and Trauma
Verified
Journal Article
Closed access
AMAzad Mojahedi
Azad Mojahedi
ASAbhijeet Singh
Abhijeet Singh
ASAmirhossein Sadeghian
Amirhossein Sadeghian
OCOn Chen
On Chen
Atrial fibrillation (AF) is increasingly prevalent in the elderly population and is associated with an elevated risk of osteoporotic fractures. This systematic review aimed to compare the risk of osteoporotic fractures between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), particularly warfarin, in patients with AF and to conduct head-to-head comparisons among different DOACs. We systematically searched literature published between January 2020 and October 2024 across multiple scientific databases. The included studies focused on adult patients with AF taking anticoagulants with fracture outcomes. We extracted and synthesized data on the fracture risk across different anticoagulant types. Our analysis revealed that DOACs, particularly rivaroxaban and apixaban, were associated with a lower fracture risk in AF patients than VKAs. Among the DOACs, apixaban appeared to have the most favorable profile for reducing hip fracture risk. Multiple studies have confirmed that DOACs are associated with decreased vertebral fracture risk compared to warfarin, with risk reductions ranging from 18-32% depending on the specific DOAC. DOACs appear to offer a safer alternative to VKAs in terms of fracture risk in patients with atrial fibrillation. This protective effect may be attributed to their lack of interference with vitamin K-dependent bone metabolism. Although evidence suggests that apixaban and rivaroxaban may have superior bone-protective profiles among DOACs, further research is needed to establish definitive comparisons between individual DOACs and elucidate their protective mechanisms.